Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Rhea-AI Summary
Atossa Therapeutics (NASDAQ: ATOS), a clinical-stage biopharmaceutical company focused on breast cancer medicines, has scheduled its fourth quarter and full year 2024 financial results conference call for Tuesday, March 25, 2025, at 8:30 a.m. ET.
The company will host both a conference call and live audio webcast to discuss corporate and financial results. Investors can access the webcast through the investor relations section of Atossa's website. For telephone access, U.S. callers should dial 1-800-836-8184, while international participants can dial 1-646-357-8785. The conference call name is 'Atossa Therapeutics Business Update'. A 30-day replay will be available on the company's website following the call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ATOS declined 3.74%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time
SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2024.
The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Atossa Therapeutics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at www.atossatherapeutics.com.
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company’s lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including metastatic, neoadjuvant, adjuvant, and prevention settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.
Contact
Michael Parks, VP Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
FAQ
When will Atossa Therapeutics (ATOS) release Q4 and full-year 2024 earnings?
How can investors access ATOS's Q4 2024 earnings call?
How long will ATOS's Q4 2024 earnings call replay be available?
What will be discussed in Atossa Therapeutics' March 25 conference call?
